The FDA and CDC are investigating reports of serious adverse events, including deaths, in recipients of Ixchiq.

A vaccine designed to protect against chikungunya, a mosquito-borne illness, has been temporarily paused for individuals aged 60 and older.

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

The diseases include dengue, chikungunya, zika and yellow fever among others. India experiences a large number of deaths due ...

The feverish diseases dengue and chikungunya could soon become endemic in Europe as the tiger mosquitoes that transmit these ...

U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya vaccine while they investigate possible ...

The FDA and CDC recommended a pause in administering Ixchiq, a chikungunya vaccine, in adults ages 60 and above after 17 serious adverse events, including two deaths.  About 80,000 Ixchiq doses have ...

A total of 19,901 dengue cases have been reported in the country so far this year, according to the National Dengue Control ...

Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed ...

Early COVID suppression could have prevented 180,000 UK deaths, study reveals … FDA, CDC pause chikungunya vaccine for adults ...

Health authorities have expedited actions to contain the soaring dengue and chikungunya cases. According to National Dengue ...